시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 골육종 시장 보고서(2025년)
Osteosarcoma Global Market Report 2025
상품코드 : 1720848
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

골육종 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 비율의 상승, 면역요법에 의한 치료 성적 개선의 가능성 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 표적 요법의 개발, 면역 요법의 발전, 맞춤형 의료의 채용, 유전자 편집 기술의 진보, 화학 요법약의 혁신, 화상 진단 기술의 향상, 수술 기술의 진보 등이 있습니다.

암의 유병률 증가는 향후 몇 년간의 골육종 시장의 확대를 촉진할 것으로 예측됩니다. 환경 노출, 감염, 유전적 소인 등, 여러 요인이 암 발생률 상승에 기여하고 있습니다. 이러한 발전은 더 나은 환자 치료, 생존율 향상, 그리고 더 효과적인 치료법의 개발로 이어집니다. 2040년까지 연간 2,990만 명의 신규 암 환자와 1,530만 명의 사망자로 증가할 가능성이 있습니다.

골육종 시장의 주요 기업은 치료 효과를 높이고 부작용을 최소화하고 환자의 생존 결과를 개선하기 위해 희귀 질병 의약품(오판 약물)에 지정된 선진 의약품 개발을 우선하고 있습니다. 희소질환용 의약품의 지정은 희소질환을 치료하도록 설계된 의약품 또는 생물제제에 규제당국이 부여한 특별한 상태이며, 세제우대조치, 임상검사지원, 시장독점권 연장 등 이점을 설명합니다. 예를 들어, 미국 제약 회사 리서터 세라퓰틱스는 2024년 4월 회사의 연구 약물 LSTA1이 미국 식품 의약국(FDA)으로부터 희귀 질병 의약품 지정을 받았습니다. LSTA1은 새로운 섭취 경로를 활성화하고 골육종 종양에 대한 약물의 침투와 축적을 향상시키는 동시에 종양 미세 환경을 변경하여 면역 요법에 대한 반응성을 향상시킬 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Osteosarcoma is a malignant tumor that develops in bone-forming cells, primarily affecting the long bones of the body. It most commonly impacts teenagers and young adults, causing symptoms such as pain, swelling, and difficulty in movement.

The primary types of osteosarcoma include intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma, the most common form, affects long bones such as the arms and legs. Originating in the bone marrow, it grows and spreads rapidly, often leading to fractures or swelling, particularly in teenagers and young adults. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. It is used for both pediatric and adult patients and is distributed through online and offline channels. The disease is managed in various settings, including hospitals and clinics, diagnostic centers, and academic and research institutions.

The osteosarcoma market research report is one of a series of new reports from The Business Research Company that provides osteosarcoma market statistics, including the osteosarcoma industry's global market size, regional shares, competitors with an osteosarcoma market share, detailed osteosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the osteosarcoma industry. This osteosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteosarcoma market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing cancer awareness, improved treatment options, a rise in bone cancer incidence, advancements in healthcare infrastructure, growth in research and clinical trials, and the development of targeted therapies and immunotherapies.

The osteosarcoma market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the rising adoption of personalized medicine, increasing awareness of rare cancers, growing government and private sector funding for research, a rising incidence of genetic mutations, and the potential for improved treatment outcomes with immunotherapy. Key trends expected during this period include the development of targeted therapies, advancements in immunotherapies, the adoption of personalized medicine, progress in gene editing techniques, innovation in chemotherapy drugs, improvements in diagnostic imaging technologies, and advancements in surgical techniques.

The increasing prevalence of cancer is expected to drive the expansion of the osteosarcoma market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells, which can invade and damage healthy tissues. Several factors contribute to the rising incidence of cancer, including an aging population, lifestyle changes, environmental exposures, infections, and genetic predisposition. Osteosarcoma treatment plays a crucial role in advancing therapeutic strategies, improving early detection techniques, and deepening the understanding of bone cancer. These developments lead to better patient care, improved survival rates, and the creation of more effective therapies. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections indicate that these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the rising prevalence of cancer is fueling the growth of the osteosarcoma market.

Major companies in the osteosarcoma market are prioritizing the development of advanced drugs with orphan drug designation to enhance treatment effectiveness, minimize side effects, and improve survival outcomes for patients. Orphan drug designation is a special status granted by regulatory agencies to drugs or biologics designed to treat rare diseases, offering benefits such as tax incentives, clinical trial support, and extended market exclusivity. For instance, in April 2024, Lisata Therapeutics Inc., a US-based pharmaceutical company, announced that its investigational drug LSTA1 received orphan drug designation from the US Food and Drug Administration (FDA). LSTA1 is designed to activate a novel uptake pathway, enhancing drug penetration and accumulation in osteosarcoma tumors while potentially modifying the tumor microenvironment to improve responsiveness to immunotherapies.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences Inc. for an undisclosed amount. This acquisition is intended to expand Telix Pharmaceuticals' oncology portfolio, reinforce its expertise in targeted cancer therapies, and strengthen its capabilities in rare disease treatments, particularly osteosarcoma. QSAM Biosciences Inc. is a US-based company specializing in osteosarcoma drug development.

Major players in the osteosarcoma market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Hikma Pharmaceuticals PLC, Spectrum Pharmaceuticals Inc., Mylan N.V., Bellicum Phamaceuticals Inc., ADVAXIS Inc., Iovance Biotherapeutics Inc.

North America was the largest region in the osteosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteosarcoma market consists of revenues earned by entities by providing services such as diagnostic services, and supportive care solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteosarcoma market also includes sales of methotrexate, doxorubicin, prosthetic implants, and immune checkpoint inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for osteosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteosarcoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Osteosarcoma Market Characteristics

3. Osteosarcoma Market Trends And Strategies

4. Osteosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Osteosarcoma Growth Analysis And Strategic Analysis Framework

6. Osteosarcoma Market Segmentation

7. Osteosarcoma Market Regional And Country Analysis

8. Asia-Pacific Osteosarcoma Market

9. China Osteosarcoma Market

10. India Osteosarcoma Market

11. Japan Osteosarcoma Market

12. Australia Osteosarcoma Market

13. Indonesia Osteosarcoma Market

14. South Korea Osteosarcoma Market

15. Western Europe Osteosarcoma Market

16. UK Osteosarcoma Market

17. Germany Osteosarcoma Market

18. France Osteosarcoma Market

19. Italy Osteosarcoma Market

20. Spain Osteosarcoma Market

21. Eastern Europe Osteosarcoma Market

22. Russia Osteosarcoma Market

23. North America Osteosarcoma Market

24. USA Osteosarcoma Market

25. Canada Osteosarcoma Market

26. South America Osteosarcoma Market

27. Brazil Osteosarcoma Market

28. Middle East Osteosarcoma Market

29. Africa Osteosarcoma Market

30. Osteosarcoma Market Competitive Landscape And Company Profiles

31. Osteosarcoma Market Other Major And Innovative Companies

32. Global Osteosarcoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteosarcoma Market

34. Recent Developments In The Osteosarcoma Market

35. Osteosarcoma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기